S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)
S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)
S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)
S&P 500   4,190.60 (-0.35%)
DOW   32,938.43 (-0.32%)
QQQ   348.62 (-0.39%)
AAPL   179.22 (+1.08%)
MSFT   330.77 (-0.13%)
META   263.77 (+0.48%)
GOOGL   123.30 (-0.30%)
AMZN   120.22 (-1.18%)
TSLA   199.96 (-0.60%)
NVDA   386.83 (-3.56%)
NIO   7.38 (-0.40%)
BABA   79.21 (+0.69%)
AMD   119.98 (-4.22%)
T   15.81 (+1.09%)
F   12.07 (-4.13%)
MU   68.58 (-4.34%)
CGC   0.81 (-4.73%)
GE   100.94 (-1.43%)
DIS   87.90 (+0.09%)
AMC   4.46 (-3.67%)
PFE   37.76 (+2.03%)
PYPL   61.82 (-0.37%)
NFLX   395.27 (+0.58%)
OTCMKTS:NVZMY

Novozymes A/S (NVZMY) Stock Forecast, Price & News

$49.69
-0.78 (-1.55%)
(As of 05/30/2023 ET)
Compare
Today's Range
$49.49
▼
$49.90
50-Day Range
$49.58
▼
$54.69
52-Week Range
$45.97
▼
$64.29
Volume
14,026 shs
Average Volume
11,094 shs
Market Capitalization
$11.29 billion
P/E Ratio
N/A
Dividend Yield
1.15%
Price Target
$370.00
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsHeadlinesShort Interest

Novozymes A/S MarketRank™ Forecast

Analyst Rating
Hold
1.88 Rating Score
Upside/​Downside
644.6% Upside
$370.00 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
8.43%
From $1.78 to $1.93 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

See Top Rated MarketRank™ Stocks Here

NVZMY stock logo

About Novozymes A/S (OTCMKTS:NVZMY) Stock

Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.

Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Stock News Headlines

May 16, 2023 | americanbankingnews.com
Novozymes A/S (OTCMKTS:NVZMY) versus Kodiak Sciences (NASDAQ:KOD) Head-To-Head Contrast
May 9, 2023 | americanbankingnews.com
Novozymes A/S (OTCMKTS:NVZMY) Receives Average Rating of "Hold" from Analysts
May 31, 2023 | Edge On The Street (Ad)
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
May 4, 2023 | americanbankingnews.com
Contrasting Gamida Cell (NASDAQ:GMDA) & Novozymes A/S (OTCMKTS:NVZMY)
April 26, 2023 | finanznachrichten.de
Novozymes A/S: Novozymes delivers stronger than expected Q1 results
April 25, 2023 | msn.com
Novozymes's Earnings: A Preview
April 25, 2023 | americanbankingnews.com
Novozymes A/S (OTCMKTS:NVZMY) vs. Entera Bio (NASDAQ:ENTX) Critical Survey
April 12, 2023 | americanbankingnews.com
Analysts Set Novozymes A/S (OTCMKTS:NVZMY) Target Price at $370.00
May 31, 2023 | Edge On The Street (Ad)
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
March 30, 2023 | finanznachrichten.de
Novozymes A/S: Novozymes' and Chr. Hansen's shareholders approve combination to create a leading global biosolutions partner
March 30, 2023 | finance.yahoo.com
Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
March 29, 2023 | americanbankingnews.com
Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update
March 28, 2023 | marketwatch.com
Novozymes, Chr. Hansen Merger Cleared by US Antitrust Regulators
March 27, 2023 | americanbankingnews.com
Critical Comparison: ProKidney (NASDAQ:PROK) versus Novozymes A/S (OTCMKTS:NVZMY)
March 16, 2023 | finance.yahoo.com
How is Novozymes OneHealth leading the probiotic market segment in FIC2023?
March 1, 2023 | bizjournals.com
Novozymes swells land holdings in Franklin County
February 25, 2023 | morningstar.com
No Major Surprises in Novozymes’ Q4 2022 Results
February 20, 2023 | investing.com
Novozymes A/S PT Lowered to DKK425 at Berenberg
January 26, 2023 | seekingalpha.com
Novozymes A/S (NVZMF) Q4 2022 Earnings Call Transcript
January 26, 2023 | finanznachrichten.de
Novozymes A/S: Novozymes delivers historically strong full-year results
January 26, 2023 | finance.yahoo.com
Novozymes delivers historically strong full-year results
January 25, 2023 | msn.com
Earnings Preview For Novozymes
January 23, 2023 | seekingalpha.com
Novozymes: Wonderful Company, Almost Reasonable Price
December 13, 2022 | msn.com
Bioscience firms Novozymes and Chr. Hansen to merge in biggest-ever Danish deal
December 12, 2022 | bloomberg.com
Novozymes Agrees to Buy Chr. Hansen in $12.3 Billion Deal
December 12, 2022 | finance.yahoo.com
Novozymes shares slide after merger with rival Chr. Hansen unveiled
December 12, 2022 | bizjournals.com
Large employer buys 50 acres in Franklin County next to its current site
See More Headlines
Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Company Calendar

Ex-Dividend for 3/22 Dividend
3/03/2023
Ex-Dividend for 3/23 Dividend
3/06/2023
Dividend Payable
3/22/2023
Dividend Payable
3/23/2023
Last Earnings
4/26/2023
Today
5/31/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Basic Materials
Current Symbol
OTCMKTS:NVZMY
CUSIP
N/A
CIK
1131345
Web
www.novozymes.com
Phone
(454) 446-0000
Fax
45-4446-9999
Employees
6,527
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$370.00
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$370.00
Forecasted Upside/Downside
+644.6%
Consensus Rating
Hold
Rating Score (0-4)
1.88
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
27.92
P/E Growth
8.94
Net Income
$500.53 million
Net Margins
20.08%
Pretax Margin
24.92%
Return on Equity
26.96%
Return on Assets
13.00%

Debt

Debt-to-Equity Ratio
0.26
Current Ratio
1.29
Quick Ratio
0.77

Sales & Book Value

Annual Sales
$2.38 billion
Price / Sales
4.75
Cash Flow
$2.16 per share
Price / Cash Flow
23.01
Book Value
$8.51 per share
Price / Book
5.84

Miscellaneous

Outstanding Shares
227,260,000
Free Float
N/A
Market Cap
$11.29 billion
Optionable
Not Optionable
Beta
0.74

Social Links


Key Executives

  • Ester Baiget
    President & Chief Executive Officer
  • Graziela Chaluppe dos Santos Malucelli
    Chief Operating Officer & Executive VP
  • Lars Green
    Chief Financial Officer & Executive Vice President
  • Claus Crone Fuglsang
    Executive Vice President-Research & Development
  • Tina Sejersgård Fanø
    EVP, Head-Agriculture & Industrial Biosolutions

Key Competitors

View All Competitors













NVZMY Stock - Frequently Asked Questions

Should I buy or sell Novozymes A/S stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last year. There are currently 2 sell ratings, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVZMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View NVZMY analyst ratings or view top-rated stocks.

What is Novozymes A/S's stock price forecast for 2023?

8 equities research analysts have issued 1 year price targets for Novozymes A/S's stock. Their NVZMY share price forecasts range from $370.00 to $370.00. On average, they predict the company's share price to reach $370.00 in the next twelve months. This suggests a possible upside of 644.6% from the stock's current price.
View analysts price targets for NVZMY or view top-rated stocks among Wall Street analysts.

How have NVZMY shares performed in 2023?

Novozymes A/S's stock was trading at $50.46 at the start of the year. Since then, NVZMY shares have decreased by 1.5% and is now trading at $49.69.
View the best growth stocks for 2023 here.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,400 shares, an increase of 88.9% from the April 30th total of 1,800 shares. Based on an average daily trading volume, of 23,600 shares, the days-to-cover ratio is currently 0.1 days.
View Novozymes A/S's Short Interest.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) issued its quarterly earnings results on Wednesday, April, 26th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by $0.03. The biotechnology company had revenue of $666.36 million for the quarter. Novozymes A/S had a net margin of 20.08% and a trailing twelve-month return on equity of 26.96%.

How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?

Novozymes A/S declared a dividend on Thursday, March 2nd. Investors of record on Monday, March 6th will be paid a dividend of $0.5898 per share on Wednesday, March 22nd. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Friday, March 3rd.
Read our dividend analysis for NVZMY.

What ETFs hold Novozymes A/S's stock?

ETFs with the largest weight of Novozymes A/S (OTCMKTS:NVZMY) stock in their portfolio include Putnam BioRevolution ETF (SYNB).Emerge EMPWR Sustainable Global Core Equity ETF (EMZA).

Is Novozymes A/S a good dividend stock?

Novozymes A/S (OTCMKTS:NVZMY) pays an annual dividend of $0.57 per share and currently has a dividend yield of 1.13%.
Read our dividend analysis for NVZMY.

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of Novozymes A/S?

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novozymes A/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $49.69.

How much money does Novozymes A/S make?

Novozymes A/S (OTCMKTS:NVZMY) has a market capitalization of $11.29 billion and generates $2.38 billion in revenue each year.

How many employees does Novozymes A/S have?

The company employs 6,527 workers across the globe.

Does Novozymes A/S have any subsidiaries?
The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.
Read More
How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The official website for the company is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000, via email at novozymesir@novozymes.com, or via fax at 45-4446-9999.

This page (OTCMKTS:NVZMY) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -